The New York Times
Thu, September 23, 2010 -- 11:40 AM ET
-----
F.D.A. and European Regulators Severely Restrict Avandia, Citing Heart Risks
In a highly unusual coordinated announcement, drug regulators
in Europe and the United States said Thursday that Avandia,
the diabetes medicine made by GlaxoSmithKline, will no longer
be widely available.
The drug's sales will be halted entirely in Europe, and
patients in the United States will be allowed to receive it
only if they have tried every other diabetes medicine and
have been made aware of the drug's substantial risks to the
heart.
The steps all but ensure that sales of Avandia -- $1.19
billion last year, and $3.2 billion as recently as 2006 --
will plunge to almost nothing as other regulators follow
suit.
Read More:
http://www.nytimes.com/2010/09/24/health/policy/24avandia.html?hp&emc=na
-----
Now get New York Times breaking news alerts sent to your mobile phone.
Sign up by texting NEWSALERTS to 698698 (NYTNYT).
-----
About This E-Mail
You received this message because you are signed up to receive breaking news
alerts from NYTimes.com.
To unsubscribe, change your e-mail address or to sign up for daily headlines
or other newsletters, go to:
http://www.nytimes.com/email
NYTimes.com
620 Eighth Ave.
New York, NY 10018
Copyright 2010 The New York Times Company
No comments:
Post a Comment